Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.07.030Source: DataRank Database

Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.74)OA: hybridTopics (28)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (26)

Shaji Kumar ORCID,Angela Dispenzieri ORCID,Dragan Jevremović ORCID,Francis K. Buadi ORCID,David Dingli ORCID

Live enrichment

PubMed:35940527 PMC:PMC9674950 OpenAlex:https://openalex.org/W4289861116

National Institutes of Health

Grant: R01 CA254961

NCI NIH HHS

Grant: P50 CA186781

National Cancer Institute

Mayo Clinic

FWCI

0.74

Citation Percentile

0.7%

Citation Trend

2023

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2022.07.030

publisherhttps://doi.org/10.1016/j.jtct.2022.07.030

publisherhttps://api.elsevier.com/content/article/PII:S2666636722015196?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722015196?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35940527

Fields of Study

Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPI3K/AKT/mTOR signaling in cancer

MeSH Terms

HumansMultiple MyelomaRetrospective StudiesTransplantation, AutologousTreatment OutcomeHematopoietic Stem Cell TransplantationInduction Chemotherapy

Keywords

MedicineMultiple myelomaAutologous stem-cell transplantationOncologyMinimal residual diseaseMelphalanInternal medicineTransplantationImmunofixationHematopoietic stem cell transplantationSurgeryBone marrowMonoclonalImmunologyMonoclonal antibodyAntibodyAutologous stem cell transplantationMass-fix

Sustainable Development Goals

SDG 0: Good health and well-being